Table 1 Fivefold cross-validation results: impact of treatments and CT images.
 |  | iCOVID |  | iCOVID w/o treatments |  | iCOVID w/o CT images |  |
---|---|---|---|---|---|---|---|
Subsets | Patients | TD-CI (%) | MADE (days) | TD-CI (%) | MADE (days) | TD-CI (%) | MADE (days) |
Cohort_1 | 394 | 76.8 (74.0–79.4) | 4.2 (3.9–4.4) | 70.8 (66.9–74.5) | 5.8 (5.3–6.3) | 77.2 (74.4–80.0) | 4.5 (4.1–4.9) |
Cohort_2 | 394 | 78.1 (75.5–80.5) | 4.1 (3.7–4.3) | 69.8 (66.6–74.1) | 6.1 (5.6–6.4) | 77.0 (74.4–79.6) | 4.3 (3.9–4.7) |
Cohort_3 | 394 | 75.3 (72.3–79.0) | 4.8 (4.5–5.2) | 69.2 (66.0–72.8) | 5.9 (5.5–6.4) | 74.4 (71.5–77.3) | 5.0 (4.7–5.3) |
Cohort_4 | 394 | 76.0 (73.2–79.1) | 4.3 (4.0–4.6) | 70.4 (66.3–74.2) | 6.2 (5.7–6.6) | 76.8 (73.9–79.4) | 4.3 (4.0–4.7) |
Cohort_5 | 393 | 73.5 (70.3–76.6) | 4.7 (4.3–5.0) | 67.4 (63.3–73.3) | 5.8 (5.4–6.1) | 72.0 (67.9–74.9) | 5.2 (4.8–5.6) |
Overall | 1969 | 74.9 (73.6–76.3) | 4.4 (4.2–4.6) | 69.1 (67.7–70.5) | 6.0 (5.7–6.2) | 74.6 (72.8–76.1) | 4.7 (4.5–4.8) |